We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

June 12, 2020

News You need - 3 Big Little Things

Commentary
Kate O'Reilly
&


Health economics outcomes evaluation; the new visitor to DTx

Read the story here.

Snapshot of the story

We need more cost effectiveness data as a collective to strengthen the case for health tech. Sleepio, a digital therapeutic that helps people with poor sleep, recently released its health economic outcomes assessment. The study was conducted at a self-insured Fortune 500 company, in collaboration with IBM Watson Health, and health economic consultant Dr. Laurence Baker.

Why this is notable:

Industry Implications:

Jane Sarasohn Kahn
Jane Sarasohn Kahn
Health Economist/Advisor, THINK-Health; Blogs at HealthPopuli
THINK-Health

Jane is an experienced health economist, and healthcare consultant, at the healthcare-technology-people interface who partners with healthcare stakeholders on strategy, scenario planning, policy, and healthcare reform. Connect with Jane to get her perspective on how cost effectiveness data is strengthening the case for digital health.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Omada making major moves on the investments stage

Read the story here.

Snapshot of the story

Omada Health recently raised a $57 million round of growth capital from the life sciences investment firm Perceptive Advisors. Omada subsequently used $30 million of that fundraise to acquire the musculoskeletal solutions company Physera. 

Why this is notable:

Industry Implications:

Lisa Suennen
Lisa Suennen
Venture Capital Investor, Entrepreneur, Advisor, Board Member
Venture Valkyrie

Lisa is a leading venture capital investor, entrepreneur and advisor, focusing on the worlds of innovation, digital transformation and frontier technologies. Connect with Lisa to get her perspective on investment trends in digital health and how partnerships are broadening the solutions landscape.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Covid-19 is no opportunity for hasty research

Read the story here.

Snapshot of the story

Two of the worlds’ leading medical journals Lancet and NEJM, have expressed concern about the accuracy of a few studies that have been published, in haste, over recent months - these papers have been retracted since. We are all living in the fast track lane, trying to get ahead and without the barriers that delay research, regulation, and market entry for our healthcare products and services. While Covid-19 has been a major driver to accelerating market pathways and diminishing market-entry barriers, we must continue to proceed with caution. While the pandemic presents certain opportunities there is not a more important time to ensure that whatever is marketed and accessible to patients is evidence-informed, safe, ethical, etc.

Why this is notable:

Industry Implications:

Jean Ledger (UCL)
Jean Ledger (UCL)
Health researcher, lecturer

Jean is an established social scientist, health researcher and lecturer at UCL who is passionate about exploring healthcare innovation and quality improvements and how they can be supported by government, policy, professionals and industry. Connect with Jean to get her perspective on addressing healthcare and social problems through evidence-based solutions.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

What are the best routes to market in DTx?

12th April @ 11:00am EDT

Join us as we discuss what are the most scalable and sustainable routes to market in DTx. Great opportunity to connect with peers and meet new people.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Masterclass - The regulation of DTx

15th April @ 10:30am EDT

Join us in this Masterclass led by Stephen Gibney from BlueBridge Technologies as we discuss the regulation of DTx. Great opportunity to Listen, engage and most importantly, enjoy.

Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Why is Medtech right for DTx and vice versa

22nd April @ 11:30am EDT

Join our Digital Health Meeting as we discuss why Medtech is right for DTx and vice versa. Apply promptly to get involved in the conversation, network with peers and share your thoughts on the topic.

Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Vivian Emmely de Ruijter
Vivian Emmely de Ruijter
Senior Manager, Digital and Technology Group, Manatt Ventures at Manatt, Phelps & Phillips, LLP
Featuring
Lisa Suennen
Lisa Suennen
Group Leader, Manatt Ventures
Vivian Emmely de Ruijter
Vivian Emmely de Ruijter
Senior Manager, Digital and Technology Group, Manatt Ventures at Manatt, Phelps & Phillips, LLP
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx - Overview of market and deals

28th April @ 10:30AM EDT

Join our Digital Health Meeting focused on the overview of market and deals in the DTx industry. Apply promptly to secure your place in the discussion and network with peers.

Featuring
Ethan Wergelis-Isaacson
Ethan Wergelis-Isaacson
Digital Health Strategy & Business Development , Otsuka Pharmaceutical Companies
Featuring
Ethan Wergelis-Isaacson
Ethan Wergelis-Isaacson
Digital Health Strategy & Business Development , Otsuka Pharmaceutical Companies

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

What are the best routes to market in DTx?

12th April @ 11:00am EDT

Join us as we discuss what are the most scalable and sustainable routes to market in DTx. Great opportunity to connect with peers and meet new people.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Robert Stern
Robert Stern
Founder & CEO, At Point Of Care
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

The future of digital medical education

13th April @ 10:30am EDT

Join us as we discuss the future of digital medical education and its impact on digital health adoption. Great opportunity to connect with peers, engage in thought-provoking conversations and meet new people.

Featuring
Joshua Landy MD
Joshua Landy MD
Chief Medical Officer, Figure 1
Meg Barron
Meg Barron
Vice President, Digital Health Strategy, American Medical Association
Featuring
Joshua Landy MD
Joshua Landy MD
Chief Medical Officer, Figure 1
Meg Barron
Meg Barron
Vice President, Digital Health Strategy, American Medical Association
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support
Clinician and Patient Engagement & Support

Role of digital patient communities in 2021

14th April @ 10:30am EDT

Join our Digital Health Meeting as we discuss the role of digital patient communities in 2021. Apply now to secure your place in the conversation and gain valuable insights from thought leaders in the industry.

Featuring
Chelsea Pan
Chelsea Pan
Partnership Engagement Manager, Verily Life Sciences
Carlos Rodarte
Carlos Rodarte
Founder & Managing Director, Volar Health LLC
Featuring
Chelsea Pan
Chelsea Pan
Partnership Engagement Manager, Verily Life Sciences
Carlos Rodarte
Carlos Rodarte
Founder & Managing Director, Volar Health LLC
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Masterclass - The regulation of DTx

15th April @ 10:30am EDT

Join us in this Masterclass led by Stephen Gibney from BlueBridge Technologies as we discuss the regulation of DTx. Great opportunity to Listen, engage and most importantly, enjoy.

Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.
Featuring
Stephen Gibney
Stephen Gibney
Quality Assurance Manager at BlueBridge Technologies
Jordan Silberman, MD, PhD
Jordan Silberman, MD, PhD
Director of Clinical Analytics and Research, Digital Care Delivery, Anthem, Inc.

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.